Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Minoxidil may improve nail growth and appearance.

The study found that combining a 655nm low-level laser helmet with 2% minoxidil resulted in better improvement in hair diameter and intermediate hair enlargement at the midscalp among Chinese women with FPHL.

This prospective randomized controlled trial found that combining platelet-rich plasma plus basic fibroblast growth factor injections with topical minoxidil significantly improves hair count and growth rate in androgenetic alopecia patients compared to either treatment alone.

In this study, the combination of topical minoxidil 5% and betamethasone valerate 0.1% achieved slightly higher depigmentation in vitiligo of hair-bearing areas but did not show significant improvement over betamethasone valerate alone.

This article lacks an abstract and presents no new findings, primarily discussing topical minoxidil sensitization in androgenic alopecia.

In this study of Indian patients with pattern hair loss, 40.8% showed low sulfotransferase enzyme activity in hair follicles, with a higher prevalence of low activity in men compared to women.

The study explored niosome formulations containing minoxidil and tretinoin and found increased drug stability and controlled release, suggesting potential as an effective drug delivery system for treating hair loss.

This abstract discusses platelet-rich plasma therapy for patterned hair loss but provides no new clinical results, suggesting further research is needed to determine its effectiveness.

Minoxidil, when used with a diuretic and β-blocking agent, can safely lower blood pressure in most children with severe hypertension due to kidney disease, with minimal side effects.

This study found that using minoxidil 2% as a mesotherapy injection showed more significant improvement in treating androgenetic alopecia in female patients than topical application.

Minoxidil helps increase hair growth and density in people with hair loss, with higher concentrations giving better results.

This study found that the ENERGI-F701 solution significantly increased hair density and reduced hair shedding in women with female pattern hair loss, with fewer local skin reactions compared to Regaine® 2% minoxidil, suggesting its effectiveness and safety as a treatment option.

This study found that a stimulating cream shampoo enhances the penetration of Minoxidil into hair follicles and scalp in a laboratory setting.

In this study, researchers developed an emulgel formulation containing minoxidil for hair growth, using chitosan and fucoidan as gelling agents, achieving controlled drug release with 99.7% released by the 12th hour.

This study observed that topical 3% minoxidil increased hair growth in treated twins compared to their untreated identical siblings.

This study found that using very-low-dose oral minoxidil (0.25 mg/d) led to improvement or stabilization of hair parameters in 40% to 60% of men with androgenetic alopecia, although results were not statistically significant for the overall group.

This study found that 32% of patients with hereditary male pattern baldness experienced cosmetically acceptable hair growth after applying topical minoxidil twice daily, with no serious side effects reported.

3% topical minoxidil effectively treats extensive alopecia areata.

In this study, topical minoxidil was found to be an effective, safe, and easy treatment for individuals with alopecia areata affecting 25–99% of the scalp, but less effective for total scalp hair loss.

In this study, 1% minoxidil lotion led to good results in 18% of male patients with androgenetic alopecia, but only 6% maintained regrowth one year after stopping treatment.

Topical minoxidil may slow hair loss but often doesn't lead to satisfactory hair regrowth and requires ongoing treatment.

This study found that 1% and 2% topical minoxidil solutions resulted in clinically noticeable hair growth compared to lower doses or placebo in men with male pattern baldness.

This source reviews the use of topical tretinoin with minoxidil for androgenetic alopecia, indicating that while combined use may convert some minoxidil nonresponders to responders, clinical evidence is limited and increased absorption may lead to irritation concerns.

This review highlights the unfounded negative perception of finasteride due to misinformation, despite its effectiveness in treating androgenetic alopecia in most men without significant drug interactions or allergy reports.

This study found that sexual side effects occurred in a small percentage of patients using combined finasteride and minoxidil, but these were not common reasons for discontinuing treatment.

This review discusses the impact of age-related hair changes on perceived attractiveness and self-perception, emphasizing the need for holistic anti-aging consultations that include hair preservation strategies.

In this study, using Trichosol™ with Minoxidil (3%) increased the percentage of hair in the anagen growth phase by about 20% over 90 days compared to using Minoxidil alone.

This article reviews various aspects of androgenetic alopecia, from its historical perceptions to current understanding and treatments, without providing new clinical results.

In this study, topical application of Tectona grandis seed extracts on albino mice significantly accelerated hair growth initiation time and increased the percentage of hair follicles in the anagenic phase compared to the standard minoxidil treatment.

This study found that tofacitinib was a safe and effective treatment for patients with moderate-to-severe alopecia areata, with a significant percentage achieving notable reductions in their Severity of Alopecia Tool scores after 18 months.